Aditxt Inc (ADTX) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
Aditxt Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Aditxt Inc 's ROA in the first quarter of 2026?
Aditxt Inc recorded a cumulative net loss of $-53 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -124.86%.
However, within the Healthcare sector 1000 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4838, from total ROA ranking in the fourth quarter of 2025 at 4939.
Aditxt s Strategic Moves: Equity Line Optimizations, Stock Consolidation, and Innovations in Cancer Detection MOUNTAIN VIEW, Calif. Aditxt, Inc. (NASDAQ: ADTX), an innovation-centric social platform, continues to solidify its foothold in the health innovations landscape by unveiling strategic updates concerning its financial and clinical pursuits. These moves underscore the company s commitment to advancing promising health solutions while maintaining disciplined financial management. Equity Line of Credit and ATM Usage Insights In a recent update, Aditxt disclosed significant activity in its financial operations by detailing the utilization of its Equity Line of Credit (ELOC) and At-the-Market (ATM) facility. Since the activation of these mechanisms, a total of 153,085,471 shares have been traded. This substantial volume indicates a strategic approach to liquidity management, ensuring the company has the necessary financial resources to support its innovation-driven agenda. Such moves often underline a company’s proactive measures in balancing shareholder value with capital requirements for new initiatives.
Aditxt, Inc. Implements a 1-for-40 Reverse Stock Split Effective October 2, 2024 Mountain View, Calif. October 2, 2024 Aditxt, Inc. (NASDAQ: ADTX), a company recognized for its innovative platform aimed at accelerating promising health advancements, has announced the implementation of a 1-for-40 reverse stock split of its common stock. This strategic financial maneuver, approved by the company s shareholders, will commence trading on a post-split basis under the same ticker symbol, ADTX, on the Nasdaq Capital Market starting from the market opening on October 2, 2024.The reverse stock split reduces the number of shares of Aditxt’s common stock by a factor of 40. This adjustment aims to increase the per-share trading price of the common stock, potentially aligning with the Nasdaq Capital Market s listing requirements and attracting a broader range of institutional investors.
Aditxt, Inc. (NASDAQ: ADTX), a pioneering company dedicated to health innovations, has recently made significant strides in the early detection of prostate cancer through its subsidiary, Pearsanta, Inc. With a current focus on precision health, Pearsanta is at the forefront of developing vital diagnostic tests, including the Mitomic Prostate Test (MPT) and the Mitomic Endometriosis Test (MET). These initiatives underscore Aditxt s commitment to improving patient outcomes, particularly in high-risk populations.In a notable development, Pearsanta has submitted a grant application to the Department of Defense s Prostate Cancer Research Program (PCRP) under the Implementation Science Award funding mechanism, seeking $2 million in non-dilutive funding. This initiative aims to bolster clinical trials for the MPT, which promises to enhance early detection capabilities for prostate cancer, a disease that often goes undiagnosed until it reaches advanced stages. The funding would facilitate the validation and implementation of this critical test, which could ultimately save lives through earlier intervention.
The Surge in Aditxt Inc. Shares: Analyzing Market Movements and Strategic MovesIn the dynamic and often unpredictable world of stock trading, a significant increase in a company s share price can generate both excitement and skepticism among investors. Aditxt Inc. (NASDAQ: ADTX), a biopharmaceutical company, has experienced a notable uptick in its stock performance, particularly following a year that saw its shares lagging behind the market average. As of mid-July 2024, Aditxt Inc. shares were reported to be trading at -97.83% below their 52-week high and only 9.63% above their 52-week low, indicating a challenging 12 months for the company. However, a closer examination of recent events surrounding Aditxt presents opportunities that may explain the positive momentum. The Financial BackdropYear-to-date, Aditxt shares have underperformed, lacking the 14.64% increase one would expect from the overall market. This discrepancy posed challenges for investors, leading to caution in trading. However, the narrative shifted recently with several events indicating that Aditxt may be on an upward trajectory.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
